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To investigate the alpha-atrial natriuretic factor in congen-
ital cardiac malformations, three groups of children, aged 7
months to 16 years, with different hemodynamic situations
were studied during routine cardiac catheterization. Twen-
ty-one (group I) had tetralogy of Fallot, 24 (group II) had a
left to right shunt with pulmonary hypertension and 12
(control group) had a minor cardiac lesion. Alpha-atrial
natriuretic factor levels were determined by a radioimmu-
noassayon blood samples from the inferior vena cava, right
atrium, pulmonary artery, left atrium and aorta. To eval-
uate the effect of an acute volume load, measurements of
hormone and pressures were repeated after right ventricu-
lography.
Alpha-atrial natriuretic factor levels varied over a wide
range in all groups and in all chambers investigated.
Nevertheless, children with pulmonary hypertension had
significantly higher levels of the hormone (p < 0.01) and
were well separated from the control group, but less well
from those with tetralogy of FaUot. A 50% increase of
alpha-atrial natriuretic factor from the inferior vena cava
to the right atrium occurred in patients with shunt lesions
with pulmonary hypertension and in patients with tetralogy
of Fallot (p < 0.001) and a further 30% increase from the
Atrial natriuretic hormone has been isolated from animals
and humans (1-5). Increased levels occur in the presence of
severe congestive heart failure of various origins (6-9)
during the state of paroxysmal supraventricular tachycardia
or atrial fibrillation (10, II) and in systemic hypertension
(12-14). Alpha-atrial natriuretic factor in now recognized as
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right atrium to the pulmonary artery (p < 0.05). After
right ventriculography, a 100% to 200% increase of alpha-
atrial natriuretic factor was observed in the total sample
(p < 0.001).
Apositive correlation was observed between right atrial
mean pressure and right atrial alpha-atrial natriuretic
factor (r = 0.63) and between pulmonary artery mean
pressure and pulmonary artery alpha-atrial natriuretic
factor (r =0.61).
Alpha-atrial natriuretic factor is thus only slightly in-
creased in the presence of pressure overload (group I) but
significantly increased in the presence of combined volume
and pressure overload (group II). Temporary right ventric-
ular volume overload with contrast medium is accompanied
by temporary pressure increase in the right atrium and
ventricle and acts as a further stimulus for alpha-atrial
natriuretic factor release. The increase of the latter between
the right atrium and pulmonary artery, statistically signif-
icant in group I and group II patients, suggests an intra-
ventricular site for alpha-atrial natriuretic factor produc-
tion and release.
(J Am Coli CardioI1990;15:1438-45)
an important regulator of blood pressure and water and
electrolyte balance in humans (15-17). However, uncer-
tainty still exists about the production centers of the hor-
mone other than the right and left atria (18,19), especially in
patients with congenital cardiac malformations.
In children with such malformations, limited information
is available regarding alpha-atrial natriuretic factor secretion
(20-31). We therefore evaluated levels of the hormone
during cardiac catheterization in children with two congen-
ital cardiac malformations with distinct hemodynamic fea-
tures: tetralogy of Fallot presenting with right ventricular
pressure overload (group I) and left to right shunt lesions
with various degrees of pulmonary artery hypertension
(group 11). A third group with minor cardiac abnormalities
served as the control group. The effect of right ventricular
0735- 1097/90/$3.50
lACC Vol. 15, No.6
May 1990:1438-45
Table 1. Description of Patients
OBERHANSLI ET AL.
ATRIAL NATRIURETIC FACTOR IN CONGENITAL HEART DISEASE
1439
Number
Mean age (yr)'
Gender (F/M)
Mean weight (kg)
Mean height (em)
Hematocrit (%)
Hemoglobin (g/100 ml)
Group I
(tetralogy of Fallot)
21
6.8 (1.8 to 14.7)
7/14
18.0 (9 to 37)
109 (83 to 154)
57.9 (36.2 to 72.5)
16.6 (12.2 to 23.2)
Group"
(left to right shunt with
pulmonary hypertension)
24
5.0 (0.6 to 13.1)
14/10
14.9 (5.5 to 33.8)
103.4 (67 to 177)
40.8 (35.4 to 59)
13.4 (10.5 to 19.8)
Control Group
(minor cardiac lesions)
12
6.2 (1.3 to 16.4)
5n
21.7 (8.4 to 45.5)
112.2 (73 to 152)
39.2 (29 to 44)
13.4 (9.5 to 14.8)
'Values in parentheses are ranges. F = female; M = male.
angiography on the release of alpha-atrial natriuretic factor
was also evaluated in these conditions.
Methods
Study patients (Table 1). The study comprised 57 chil-
dren, aged 7 months to 16 years, undergoing elective pre-
operative cardiac catheterization for a congenital cardiac
malformation. Twenty-one patients had tetralogy of Fallot
(group I), 24 patients had a left to right shunt lesion (group
Il), with ventricular volume overload and various degrees of
pulmonary hypertension in 21 and no or minimal elevation of
pulmonary artery pressure in 3, and 12 patients had only
minor cardiac abnormalities (the control group). This latter
group included five children operated on for a ventricular or
atrial septal defect several months or years earlier; four
others had mild pulmonary or aortic stenosis and the other
three were studied because of arrhythmias. The primary
diagnosis was established by clinical investigation, two-
dimensional echocardiography, Doppler evaluation and
measurement of atrial, arterial and ventricular diameters by
M-mode ultrasonography. Thirteen of the 21 group I patients
were given beta-blocking medication (propranolol, 1 to 5
mg/kg body weight per day); 16 of the 24 children in group II
were given digoxin (10 lLg/kg per day) and 9 of the group II
patients were also given furosemide (2 to 3 mg/kg per day).
Creatinine, electrolyte and protein plasma concentrations
were normal.
The study protocol was approved by the local Research
Board and the Ethics Committee of the Pediatric Depart-
ment of the University of Geneva. Informed consent was
obtained from parents or tutors.
Cardiac catheterization. After a 6 to 12 h fasting period,
patients were sedated in the morning, 60 min before cardiac
catheterization, with a "cocktail" of dichlorpromazine,
promethazine and pethidine. A complete right and left heart
hemodynamic study was performed. Pressure measurements
were obtained by a standardized method under baseline
conditions and after right ventricular angiography with I
ml/kg of contrast medium in patients with tetralogy of Fallot
and control patients and 1.5 to 2 ml/kg in patients with a
shunt and pulmonary hypertension. In addition, in seven
patients a continuous right atrial mean pressure measure-
ment was possible during angiography through a second
venous catheter placed in the right atrium. The contrast
medium used, iopamidol, is nonionic, low osmolar, hyper-
viscous and has an elimination half-life of 2 h.
Alpha-atrial natriuretic factor. Plasma concentrations of
alpha-atrial natriuretic factor were determined before and
after right ventricular angiography in the inferior vena cava,
right atrium, pulmonary artery, aorta and left atrium when
entered. For ethical reasons, blood sampling of a maximum
of 16 ml blood was accepted for the study in children
weighing> 10 kg. Blood samples of 2 ml were obtained in a
rapid sequence at the sites mentioned for measurements of
alpha-atrial natriuretic factor and oxygen saturation; 1.5 ml
of each sample was transferred into chilled, siliconized
disposable tubes containing Trasylol (aprotinin) and ethyl-
enediaminetetraacetic acid (EDTA), then immediately
placed on ice and promptly centrifuged. The plasma was
adjusted to a pH of4 and immediately frozen at - 20°C. After
extraction, a radioimmunoassay using the iodine-125-
labeled alpha-atrial natriuretic factor (produced by Amer-
sham International), and the antibody (supplied by Peninsula
Laboratories) was performed for alpha-atrial natriuretic fac-
tor determination, as described elsewhere (32). The number
of samples analyzed for each group appears in Figure 1. For
our laboratory, the intra- and interassay variation coeffi-
cients were 10.9% and 13.5%, respectively. The recovery of
alpha-atrial natriuretic factor after the extraction procedure
was 79%.
Statistical analysis. A log transformation of alpha-atrial
natriuretic factor values was used to stabilize the variances
and to normalize the distribution. One-way analysis of
variance was used to compare the three groups with use of
Welch's test when the variances were considered to be
different by the Levene test. In case of significant differences
among groups, pairwise comparison of means with the
Bonferroni criterion were performed. Two-sided p values
<0.05 were considered significant. With the clinical and
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Figure l. Concentrations of atrial
natriuretic factor (ANF) (pglml) (A) in
children with tetralogy of Fallot (group
I); (B) in children with a left to right
shunt lesion and pulmonary hyperten-
sion (group II); and (C) in children with
minor cardiac lesions (control group).
Note the increase of alpha-atrial natri-
uretic factor concentrations from the
inferior vena cava (lVC) to the right
atrium (RA) and to the pulmonary ar-
tery (PA) and the aorta (Ao), before
(triangles) and after (circles) right ven-
triculography (angio). A rather wide
dispersion of individual values exists
within the three groups. The number of
plasma measurements obtained, the
'1lean values (m) and the standard de-
viations are shown below each graphic
presentation.
C
•
400
300 •
200 •
100~ 1 •..A0
lye
n =12
m=56±34
RA
n =11
m =70 ± 27
PA
n .12
m=90±35
Ao lye
"=11 "=6
m = 78 ± 42 m =180 ± 103
RA PA Ao
"=7 n =6 n =6
m = 260 ± 89 m. 207 ± 58 m = 221 ± 174
lACC Vol. 15. No.6
May 1990: 1438-45
OBERHANSLI ET AL.
ATRIAL NATRIURETIC FACTOR IN CONGENITAL HEART DISEASE
1441
Table 2. Hemodynamic Variables and Plasma Concentration of Immunoreactive Alpha-atrial Natriuretic Factor in 57 Children
Group I Group II Control Group
Before A After A Before A After A Before A After A
No. of 21 19 24 23 12
measurements
QP/QS 0.7 (O.I to 1.2) 2.8 (I to 7.2) 1.0 (I.0 to 1.2)
Pressures (mm Hg)
Mean
RA 6 (I to 22) 9 (3 to 27) 4 (I to 10) 7 (2 to 12) 2.5 (I to 4) 6 (3 to 12)
RV S 107 (40 to 200) 112 (83 to 190) 64 (26 to 105) 72 (32 to 120) 29 (16 to 55) 38 (20 to 65)
RVD 9 (4 to 24) 11 (6 to 30) 7 (3 to 12) 9 (4 to 18) 5 (4 to 8) 8 (4 to 14)
PA 13 (6 to 20) 15 (10 to 20) 42 (14 to 73) 50 (19 to 84) 14 (9 to 21) 23 (11 to 42)
LA 7 (3 to 12) 9 (6 to 13) 12 (6 to 22) 12 (11 to 14) 7 (4 to 10) 10 (10)
AO 80 (60 to 120) 87 (62 to 132) 74 (60 to 85) 77 (63 to 90) 76 (66 to 90) 77 (56 to 92)
a-ANF (pg/mll
Mean
IVC 68 (10 to 169) 217 (42 to 612) 198 (10 to 1.417) 412 (63 to 1,568) 56 (28 to 162) 181 (70 to 346)
RA 114 (10 to 308) 298 (21 to 875) 360 (10 to 1.655) 594 (45 to 2.275) 70 (35 to 122) 260 (122 to 378)
[*188 (10 to 1.662) 417 (21 to 2,310))
PA 139 (10 to 262) 33 t (49 to 805) 456 (10 to 1.697) 883 (74 to 3.220) 90 (46 to 147) 207 (105 to 266)
LA 128 (24 to 210) 228 (77 to 525)
AO 133 (10 to 365) 360 (95 to 910) 336 (10 to 1.190) 760 (116 to 1.960) 78 (38 to 168) 221 (66 to 567)
M-mode echo
Ratio LNAO 1.0 (0.73 to 1.5) 1.5 (1.0 to 2.1) 1.1 (1.0 to 1.2)
diameter
Values in parentheses are ranges. Groups are defined as in Table I. * = with inclusion of the patient in right heart failure. A = angiography; a-ANF = plasma
alpha-atrial natriuretic factor; AO = aorta; D = diastole: echo = echocardiography: IVC = inferior vena cava: LA = left atrium; PA = pulmonary artery;
QP = pulmonary flow; QS = systemic flow: RA = right atrium; RV = right ventricle: S = systole.
laboratory data and the hemodynamic variables, we per-
formed a stepwise discriminant analysis. Linear regression
analyses were carried out between hemodynamic variables
and alpha-atrial natriuretic factor values.
Results
Hemodynamic findings (Table 2). The hemodynamic var-
iables differ significantly among groups but are rather similar
within each study group. All patients with tetralogy of Fallot
(group I) had very low pulmonary artery mean, systolic and
diastolic pressures, systemic pressures in the right ventricle
and a dominant right to left shunt. Only one patient in this
group was in right heart failure with a mean right atrial
pressure of 22 mm Hg at cardiac catheterization.
Pulmonary artery pressure varied among the patients
with a left to right shunt (group 11). Pulmonary hypertension
was severe in three patients who had developed a bidirec-
tional shunt, whereas three had normal pulmonary artery
pressures. All patients except the three with Eisenmenger
syndrome had a very high pulmonary artery flow rate and a
pulmonary to systemic flow ratio >2.
In the control group, 4 of the 12 patients still had mildly
increased pulmonary artery pressures, although their shunt
lesion had been surgically closed >6 months earlier; the
other 8 patients had no shunt and had normal hemodynamic
variables.
Plasma alpha-atrial natriuretic factor concentrations (Ta-
ble 3). Group I. Patients with tetralogy ofFallot malforma-
tion. Mean plasma values in these patients were slightly but
insignificantly higher than in the control group and compared
with reported values in children with tetralogy of Fallot
malformation (20-22,24,29). Alpha-atrial natriuretic factor
concentrations varied within the groups over a wide range
(Fig. I). There was one patient with extremely high plasma
values (l,662 pg/ml) presenting with right heart failure (as
mentioned earlier). A stepwise increase in plasma values
Table 3. Atrial Natriuretic Factor: Ratio of Means With 95%
Confidence Intervals
Group I Group II Control Group
RA/IVC 1.62 (1.21 to 2.16) 1.60 (1.23 to 2.08) 1.41 (0.97 to 2.04)
PA/RA 1.36 (1.05 to 1.76) 1.29 (1.01 to 1.64) 1.18 (0.84 to 1.67)
PA/IVC 2.05 (1.50 to 2.80) 2.07 (1.55 to 2.77) 1.69 (1.15 to 2.48)
AO/PA 0.94 (0.72 to 1.22) 0.92 (0.72 to 1.18) 0.78 (0.56 to 1.09)
AO/IVC 1.84 (1.42 to 2.38) 1.88 (1.47 to 2.41) 1.43 (1.03 to 1.99)
*Ditferences of atrial natriuretic factor concentration between chambers
in log scale were "back"·transformed to present the ratio of ANF means
together with the 95% confidence levels by use of Bonferroni criteria. Groups
are as defined in Table I; abbreviations as in Table 2.
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Figure 2. Right ventriculography (an-
gio) with 1 to 2 ml/kg of contrast me-
dium produces a very significant in-
crease in alpha-atrial natriuretic factor
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occurred from the inferior vena cava to the pulmonary artery
and to the aorta (p < 0.001) (Table 3). No significant
differences existed between plasma alpha-atrial natriuretic
factor concentrations in patients receiving a beta-adrenergic
blocking agent or in those without medication.
Group 1I. Patients with left to right shunt and pulmonary
hypertension. Plasma alpha-atrial natriuretic factor concen-
trations in these patients were significantly higher than in the
control group except in the inferior vena cava. No clear
separation was possible between groups I and II as a result
of the marked variations of individual values within groups
and im important overlap: the three children who had a left
to right shunt and normal pulmonary artery pressure had the
lowest alpha-atrial natriuretic factor values. A significant
and similar increase in plasma concentration occurred before
a.nd after angiography between the inferior vena cava and the
right atrium (p < 0.(01) but also between the right atrium and
the pulmonary artery (p < 0.03) (Table 3). No significant
difference was observed for alpha-atrial natriuretic factor
values among children treated with digoxin or diuretics, or
both, and untreated patients.
Angiography (Fig. 2). Right ventriculography produced a
similar increase in alpha-atrial natriuretic factor excretion in
all chambers in all three groups. This increase in plasma
concentration was paralleled by a temporary increase in
mean right atrial and right ventricular diastolic pressures.
Regression analyses (Fig. 3). For the total group, a posi·
tive correlation was found between right atrial mean pres-
sure and right atrial alpha-atrial natriuretic factor concentra-
tion (r = 0.63, p < 0.01) and between right atrial and
pulmonary artery mean pressures and pulmonary alpha-
atrial natriuretic factor values (r = 0.61, P < 0.01). A
stepwise linear regression analysis for the total group se-
lected mean pulmonary artery pressure, left atrial to aortic
diameter ratio and mean right atrial pressure as independent
predictors for right atrial (R2 = 0.79) and pulmonary artery
(R2 = 0.84) alpha-atrial natriuretic factor values, respec-
tively.
Discussion
In the present study, we determined alpha-atrial natri-
uretic factor excretion in three age-matched groups of chil·
dren with very different congenital cardiac diseases and
distinct and typical hemodynamic conditions. We also tried
to characterize these cardiac conditions on the basis of
alpha-atrial natriuretic factor concentrations.
Concentration of alpha-atrial natriuretic factor in different
cardiac malformations. Plasma concentration measurements
in all three groups were higher than reported values in
normal children (20-24,29-31). In our study, a clear-cut
separation of groups on the basis of alpha-atrial natriuretic
lACC Vol. 15. No.6
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(20-24,26,27), whereas we studied serial concentrations in
various intracardiac sites.
The increase from the inferior vena cava to the right
atrium and from the right atrium to the pulmonary artery in
our group I and group II patients suggests that an important
alpha-atrial natriuretic factor release occurs not only in the
right and left atria but also in the ventricles. Indeed, produc-
tion centers other than the atria have been found in animal
studies (8,19,33-35), in human fetuses and recently also in
human adults (18,35-37). Cardiocytes containing increased
levels of immunoreactive alpha-atrial natriuretic factor were
isolated in ventricles of different species (35), and the
hormone released from ventricular cardiocytes was shown
to reach cardiac cavities partially through the great cardiac
veins that drain into the coronary sinus (37) and it is
probably also released directly into the ventricles. Because
production of alpha-atrial natriuretic factor exists in fetal
ventricles, we can only assume that an embryonic expres-
sion of hormone production centers in the ventricular cardi-
ocytes that regresses under normal conditions by the end of
pregnancy and after birth (20,38) is preserved in children
with congenital cardiac malformations. Alternatively, this
expression may be reinitiated when acquired heart diseases
occur in children and adults, especially in association with
heart failure. In our present study group, no significant
age-related variations were observed, but neonates, infants
and very young children were, for ethical reasons, not
included in this protocol. The significant decrease of alpha-
atrial natriuretic factor concentration from the aorta to the
inferior vena cava is probably related to a high number of
alpha-atrial natriuretic factor receptors all over the body and
to rapid catabolism of the hormone.
Angiography and the release of alpha-atrial natriuretic
factor. An acute volume load with a temporary pressure
increase in the right atrium and ventricle resulting from right
ventriculography induced a 100% to 200% increase in alpha-
atrial natriuretic factor levels in the total study group; no
significant difference occurred among the three subgroups.
The contrast injection thus produced a stimulus for the
release of atrial natriuretic factor whether the initial levels
under baseline conditions were high or not. Because we used
iopamidol, a nonionic, low osmolar but hyperviscous con-
trast medium, a chemical stimulus for the release of alpha-
atrial natriuretic factor seems unlikely; thus, a combined
stretch and pressure effect is probably the mechanism for the
release of this hormone (Table 2, Fig. 1). This observation
also suggests large reserves and additional production ca-
pacities.
Correlation of plasma alpha-atrial natriuretic factor and
hemodynamic variables. In children with congenital cardiac
malformations, the influence of the different hemodynamic
variables on release of alpha-atrial natriuretic factor is
mostly unknown (20,23-30). It has been speculated that
increased hormone levels are directly related to elevated
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Figure 3. Apositive correlation is shown between pulmonary artery
mean pressure (mm Hg) and pulmonary artery (PA) alpha-atrial
natriuretic factor (a-ANF) (pg/ml) for the total study group (y =
16,5, X-lOS; r = 0.61; p < 0.001). Abbreviations as in Figure 2.
factor values was possible only between control patients and
those with pulmonary hypertension (group 11). Children with
a shunt and with pulmonary hypertension, although receiv-
ing digitalis or a diuretic, or both, had higher plasma values
than did patients with tetralogy of Fallot (group I) and
control patients in the various sampling sites, thus con-
firming some of the previously reported observations when
only peripheral venous blood samples were analyzed
(20,24,26-28). As a result of very important variations within
groups, the differences were statistically significant only
between control patients and group II patients; the overlap
among groups was especially important between control
patients and those with tetralogy of Fallot, but it was also
present among the other groups. Unfortunately, our study is
lacking an entirely normal reference group, but for ethical
reasons such a study in normal children is not possible.
Release of alpha-atrial natriuretic factor in atria and
ventricles. Plasma values increased from the inferior vena
cava to the right atrium and pulmonary artery in the total
study group. Such findings were reported in some earlier
studies in adults with congestive cardiomyopathy. In this
condition there is a hypocontractile ventricle in contrast to
the hypercontractile ventricle in children with a left to right
shunt or tetralogy of Fallot. Except for two studies (29,30),
the reported plasma alpha-atrial natriuretic factor values in
children with congenital cardiac malformations have relied
on determinations in peripheral venous blood samples only
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pulmonary artery pressure at birth (20). We tried to correlate
several variables (including echocardiographically deter-
mined left atrial to aortic diameter ratio, pulmonary artery
pressure, right atrial mean pressure, pulmonary to systemic
flow ratio) with the corresponding values of atrial natriuretic
factor. Correlations were obtained in all these analyses with
the best results obtained between right atrial and pulmonary
artery mean pressures and alpha-atrial natriuretic factor
plasma levels in the corresponding location (r = 0.63 and r =
0.61, respectively) (Fig. 3). A multivariate analysis for the
total study group suggests that pulmonary artery pressure is
as important as right atrial pressure and right atrial dimen-
sion for the prediction of alpha-atrial natriuretic factor
concentration in the pulmonary artery and aorta; the large
variations in concentrations within groups are still not com-
pletely explained by the individual hemodynamic variables.
However, the different degrees of pressure or volume over-
load, or both, with different degrees of congestive heart
failure do play an important role. Digitalis and diuretic
treatment in most of our patients with a shunt lesion could
have influenced this correlation, but the limited number of
patients does not allow detailed analyses in this study.
Indeed, 16 of the 24 patients were receiving digitalis and 9 of
them were receiving both digitalis and a diuretic.
Conclusions. Our results show that different congenital
cardiac malformations present with different plasma concen-
trations of atrial natriuretic factor. The differences in hor-
mone levels within groups are probably related to the very
specific hemodynamic status of each patient. In congenital
cardiac malformations with volume or pressure overload, or
both, the hormone release occurs probably not only in the
atria but also in the ventricles. An adequate stimulus liber-
ates further alpha-atrial natriuretic factor even when initial
levels at baseline conditions are already markedly increased.
To evaluate the influence of digoxin and diuretics on alpha-
atrial natriuretic factor production, further studies with a
large number of patients will be necessary. In congenital
heart disease, the postulated release of atrial natriuretic
factor in the ventricles needs further investigation on ven-
tricular biopsy material, with emphasis on histochemical and
histopathologic aspects.
We are grateful to Marie-Helene Decruy. Martine Gourgeon, Jean-Jacques
Adatte, Jean-Jacques Bodenmann and Jean-Pierre Killisch for their excellent
technical assistance, to Marie-Fran~oise Dufaud for secretarial help and
Daniel Furrer for preparing the graphic presentations.
References
I. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and
potent natriuretic response to intravenous injection of atrial myocardial
extract in rats. Life Sci 1981 ;28:89-94.
2. de Bold AJ. Atrial natriuretic factor: a hormone produced by the heart.
Science 1985;230:767-70.
3. Atlas SA, Kleinert HD, Camargo MJ, et al. Purification, sequencing and
synthesis of natriuretic and vasoactive rat atrial peptide. Nature 1984;309:
717-9.
4. Kangawa K, Matsuo H. Purification and complete amino acid sequence of
a-human atrial polypeptide (a-hANP). Biochem Biophys Res Commun
1984:118: 131-9.
5. Yandle TG, Espiner EA, Nicholls G, Duff H. Radioimmunoassay and
characterization of atrial natriuretic peptide in human plasma. J Clin
Endocrinol Metab 1986;63:72-9.
6. Raine AEG, Erne P, Biirgisser E, et al. Atrial natriuretic peptide and
atrial pressure in patients with congestive heart failure. N Engl J Med
1986:315:533-7.
7. Hirata Y, Ishii M, Mastuoka H. et al. Plasma concentrations of a-human
atrial natriuretic polypeptide and cyclic GMP in patients with heart
disease. Am Heart J 1987;113:1463-9.
8. Riegger GA, Elsner G, Kromer EP, et al. Atrial natriuretic peptide in
congestive heart failure in the dog: plasma levels, cyclic guanosine
monophosphate, ultrastructure of atrial myoendocrine cells, and hemo-
dynamic, hormonal, and renal effects. Circulation 1988;77:398-406.
9. Sugawara A, Nakao K, Morii N, et ai. Synthesis of atrial natriuretic
polypeptide in human failing hearts. J Clin Invest 1988;81:1962-70.
10. Roy D, Paillard F, Cassidy D, et al. Atrial natriuretic factor during atrial
fibrillation and supraventricular tachycardia. J Am Coli Cardiol 1987;9:
509-14.
II. Tsai RC, Yamaji T, Ishibashi M, et ai. Atrial natriuretic peptide during
supraventricular tachycardia and relation to hemodynamic changes and
renal function. Am J Cardiol 1988;61:1260-4.
12. Hamet P. Effect of natural and synthetic atrial natriuretic factor on atrial
blood pressure, natriuresis and cyclic GMP excretion in spontaneously
hypertensive rats. Clin Sci 1985:69:721-6.
13. Needleman P, Greenwald JE. Atriopeptin: a cardiac hormone intimately
involved in fluid electrolyte and blood pressure homeostasis. N Engl J
Med 1986;314:828-34.
14. Bolli P, Muller FB, Linder L, et al. Greater vasodilator responsiveness to
atrial natriuretic peptide in low-renin essential hypertensives. J Hypertens
1987;5:S55-8.
15. Saxenhofer H, Weidmann P. Pharmakologische Effekte des atrialen
natriuretischen Peptids beim Mechen. Z Kardiol 1988;77:6-10.
16. Indolfi C, Piscione F, Volpe M, et al. Cardiac effects of atrial natriuretic
peptide in subjects with normal left ventricular function. Am J Cardiol
1989;63:353-7.
17. Roy LF, Ogilvie RI, Larochelle P, Hamet P, Leenen F. Cardiac and
vascular effects of atrial natriuretic factor and sodium nitroprusside in
healthy men. Circulation 1989;79:383-92.
18. Tsuchimochi H, Kurimoto F, leki K, et al. Atrial natriuretic peptide
distribution in fetal and failed adult human hearts. Circulation 1988;78:
920-7.
19. Ding J, Thibault G, Gutkowska J, et al. Cardiac and plasma atrial
natriuretic factor in experimental congestive heart failure. Endocrinology
1987:121:248-57.
20. Weil J, Bidlingmaier F. DOhlemann C, Kuhnle U, Strom T, Lang RE.
Comparison of plasma atrial natriuretic peptide levels in healthy children
from birth to adolescence and in children with cardiac diseases. Pediatr
Res 1986:20: 1328-3 I.
21. Kikuchi K, Shiomi M. Horie K. et al. Plasma atrial natriuretic polypep-
tide concentration in healthy children from birth to adolescence. Acta
Paediatr Scand 1988:77:380-4.
22. Weil J, Strom TM, Heim JM, et al. Influence of diurnal rhythm, posture
and right atrial size of plasma atrial natriuretic peptide levels. Z Kardiol
1988:77:36-40.
23. Rascher W, Tulassay T, Lang RE. Atrial natriuretic peptide in plasma of
volume-overloaded children with chronic renal failure. Lancet 1985:2:
303-5.
JACC Vol. 15, No.6
May 1990:1438-45
OBERHANSLI ET AL.
ATRIAL NATRIURETIC FACTOR IN CONGENITAL HEART DISEASE
1445
24. Kikuchi K, Nishioka K, Ueda T, et al. Relationship between plasma atrial
natriuretic polypeptide concentration and hemodynamic measurements in
children with congenital heart diseases. J Pediatr 1987;111 :335-42.
25. Oberhansli I, Favre H, Friedli B, Girardin E, Paunier L. Atrial natriuretic
factor in congenital heart disease before and after angiography (abstr).
Eur Heart J 1988;9:251.
26. Matsuoka S, Karahashi Y, Tomimatsu H, et al. Plasma atrial natriuretic
peptide levels in patients with ventricular septal defects. J Pediatr
1987;110:578-80.
27. Andersson S, Tikkanen I, Pesonen E, Meretoja 0, Hynynen M, Fyhrquist
F. Atrial natriuretic peptide in patent ductus arteriosus. Pediatr Res
1987;21:396-8.
28. Andersson S, Tikkanen I, Pesonen E. Wallgren E1, Fyhrquist F. Atrial
natriuretic peptide and atrial pressures in newborns with transposition of
the great arteries. Acta Paediatr Scand 1988;77:72-5.
29. Matsuoka S, Kurahashi Y, Miki Y, et aJ. Plasma atrial natriuretic peptide
in patients with congenital heart diseases. Pediatrics 1988;82:639-43.
30. Ross RD, Daniels SR, Dolan LM, Young CA, Meyer RA. Determinants
of plasma atrial natriuretic factor concentrations in congenital heart
disease. Am J Cardiol 1988;62:785-8.
31. Schmidt KG, Cloez JL, Rascher W, Lange RE. Atrial natriuretic peptide
in congenital heart defects with right heart volume overload (abstr). J Am
Coli Cardiol1988;ll(suppl A):137A.
32. Larose P, Meloche S, Du Souich P, Delean A, Ong H. Radioimmunoas-
say of atrial natriuretic factor: human plasma levels. Biochem Biophys
Res Commun 1985;130:553-8.
33. Nemer M, Lavigne JP, Drouin J, Thibault G. Expression of atrial
natriuretic factor gene in heart ventricular tissue. Peptides 1986;7:1147-
52.
34. Wei H, Rodi CP, Day MD, et aJ. Developmental changes in the rat
atriopeptin hormonal system. J Clin Invest 1987;79:1325-9.
35. Seidman CEo Expression of atrial natriuretic factor in the normal and
hypertrophied heart. Heart Failure 1989;5: 130-4.
36. Kikuchi K, Nakao K, Hayashi K, et a!. Ontogeny of atrial natriuretic
polypeptide in the human heart. Acta EndocrinoI1987;115:211-7.
37. Yasue H, Obata K, Okumura K, et a!. Increased secretion of atrial
natriuretic polypeptide from the left ventricle in patients with dilated
cardiomyopathy. J Clin Invest 1989;83:46-51.
38. TulassayT, Rascher W, Seyberth HW, Lang RE, Toth M, Sulyok E. Role
of atrial natriuretic peptide in sodium homeostasis in premature infants.
J Pediatr 1986;109:1023-7.
